Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer
Jiawei Chen; Hongsheng Deng; Jiaxi He; Zhufeng Wang; Shuben Li · 2022 · Frontiers in Oncology
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
IntroductionThe interval between neoadjuvant immunochemotherapy and surgery in patients with non-small cell lung cancer (NSCLC) has not been well characterized. This study investigated the association between the time-to-surgery (TTS) interval and surgical–pathological outcomes.MethodClinical data of patients who received neoadjuvant immun-ochemotherapy followed by surgery for NSCLC between January 2019 and September 2021 were collected. The patients were divided into three groups based on TTS interval: the early-surgery group (ESG), the standard-surgery group (SSG), and the delayed-surgery gr
Abstract by Jiawei Chen; Hongsheng Deng; Jiaxi He; Zhufeng Wang; Shuben Li, Frontiers in Oncology (2022) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
Effects of Src on Proliferation and Invasion of Lung Cancer Cells
Negative / Null Result ReportSecretory Function of Kupffer Cells in Liver Cancer After Cryoablation
Negative / Null Result ReportEffect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain
Negative / Null Result ReportImpact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9
Negative / Null Result ReportSingle-fraction SRS and multiple-fraction SRT for brain metastases from colorectal cancer
Negative / Null Result ReportAnti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: DOAJ · DOI 10.3389/fonc.2022.909726